Top

Published in:

01-10-2012 | Mini Review

PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas

Authors: Hadara Rubinfeld, Ilan Shimon

Published in: Endocrine | Issue 2/2012

Abstract

Non-functioning pituitary adenomas (NFPAs) comprise a heterogeneous group, which are considered the most common pituitary tumor. As no clinically hormone hypersecretion is apparent, non-functioning pituitary adenomas are often diagnosed only when they are large enough to cause tumor mass effects, such as hypopituitarism, visual field defects or headaches. Efficient medical therapy for NFPAs is currently unavailable and surgical treatment of these tumors is not always satisfactory. Characterization of signaling regulatory events in the context of NFPAs may enable the development of new attractive novel strategies. Although data regarding gene expression profiling of signaling pathways in NFPAs have accumulated, studies aimed at fine-classification of NFPAs-specific signaling regulatory mechanisms and feedback loops are scarce.

F. Roelfsema, N.R. Biermasz, A.M. Pereira, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15, 71–83 (2011)CrossRef

A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, S. Savastano, Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15(4), 905–915 (2008)PubMedCrossRef

M.A. Tichomirowa, A.F. Daly, A. Beckers, Treatment of pituitary tumors: somatostatin. Endocrine 28(1), 93–100 (2005)PubMedCrossRef

A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, U. Schoenherr, B. Dipl, D. Mills, L.R. Salgado, B.M. Biller, A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med. 366(10), 914–924 (2012)PubMedCrossRef

M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94(1), 115–122 (2009)PubMedCrossRef

M.S. Elston, A.J. Gill, J.V. Conaglen, A. Clarkson, J.M. Shaw, A.J. Law, R.J. Cook, N.S. Little, R.J. Clifton-Bligh, B.G. Robinson, K.L. McDonald, Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149(3), 1235–1242 (2008)PubMedCrossRef

N.A. Hibberts, D.J. Simpson, J.E. Bicknell, J.C. Broome, P.R. Hoban, R.N. Clayton, W.E. Farrell, Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin. Cancer Res. 5(8), 2133–2139 (1999)PubMed

S. Jordan, K. Lidhar, M. Korbonits, D.G. Lowe, A.B. Grossman, Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur. J. Endocrinol. 143(1), R1–R6 (2000)PubMedCrossRef

D.J. Simpson, S.J. Frost, J.E. Bicknell, J.C. Broome, A.M. McNicol, R.N. Clayton, W.E. Farrell, Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 22(8), 1149–1154 (2001)PubMedCrossRef

10.

H.E. Turner, Z. Nagy, N. Sullivan, M.M. Esiri, J.A. Wass, Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin. Endocrinol. (Oxf) 53(3), 337–344 (2000)CrossRef

11.

V. Chesnokova, S. Zonis, C. Zhou, A. Ben-Shlomo, K. Wawrowsky, Y. Toledano, Y. Tong, K. Kovacs, B. Scheithauer, S. Melmed, Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6(3), e17924 (2011)PubMedCrossRef

12.

G.M. Pierantoni, P. Finelli, E. Valtorta, D. Giardino, O. Rodeschini, F. Esposito, M. Losa, A. Fusco, L. Larizza, High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr. Relat. Cancer 12(4), 867–874 (2005)PubMedCrossRef

13.

C.S. Moreno, C.O. Evans, X. Zhan, M. Okor, D.M. Desiderio, N.M. Oyesiku, Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 65(22), 10214–10222 (2005)PubMedCrossRef

14.

X. Zhang, Y. Zhou, K.R. Mehta, D.C. Danila, S. Scolavino, S.R. Johnson, A. Klibanski, A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J. Clin. Endocrinol. Metab. 88(11), 5119–5126 (2003)PubMedCrossRef

15.

J. Zhao, D. Dahle, Y. Zhou, X. Zhang, A. Klibanski, Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 90(4), 2179–2186 (2005)PubMedCrossRef

16.

K.J. Dudley, K. Revill, R.N. Clayton, W.E. Farrell, Pituitary tumours: all silent on the epigenetics front. J. Mol. Endocrinol. 42(6), 461–468 (2009)PubMedCrossRef

17.

D.A. Altomare, J.R. Testa, Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50), 7455–7464 (2005)PubMedCrossRef

18.

I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489–501 (2002)PubMedCrossRef

19.

Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, Y. Lu, Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr. Relat. Cancer 16(1), 301–310 (2009)PubMedCrossRef

20.

M. Musat, M. Korbonits, B. Kola, N. Borboli, M.R. Hanson, A.M. Nanzer, J. Grigson, S. Jordan, D.G. Morris, M. Gueorguiev, M. Coculescu, S. Basu, A.B. Grossman, Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr. Relat. Cancer 12(2), 423–433 (2005)PubMedCrossRef

21.

M. Xu, L. Shorts-Cary, A.J. Knox, B. Kleinsmidt-DeMasters, K. Lillehei, M.E. Wierman, Epidermal growth factor receptor pathway substrate 8 is overexpressed in human pituitary tumors: role in proliferation and survival. Endocrinology 150(5), 2064–2071 (2009)PubMedCrossRef

22.

D. Dworakowska, E. Wlodek, C.A. Leontiou, S. Igreja, M. Cakir, M. Teng, N. Prodromou, M.I. Goth, S. Grozinsky-Glasberg, M. Gueorguiev, B. Kola, M. Korbonits, A.B. Grossman, Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer 16(4), 1329–1338 (2009)PubMedCrossRef

23.

U. Pagotto, T. Arzberger, M. Theodoropoulou, Y. Grubler, C. Pantaloni, W. Saeger, M. Losa, L. Journot, G.K. Stalla, D. Spengler, The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 60(24), 6794–6799 (2000)PubMed

24.

T.W. Noh, H.J. Jeong, M.K. Lee, T.S. Kim, S.H. Kim, E.J. Lee, Predicting recurrence of nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 94(11), 4406–4413 (2009)PubMedCrossRef

25.

M. Theodoropoulou, G.K. Stalla, D. Spengler, ZAC1 target genes and pituitary tumorigenesis. Mol. Cell. Endocrinol. 326(1–2), 60–65 (2010)PubMedCrossRef

26.

Y. Yin, W.H. Shen, PTEN: a new guardian of the genome. Oncogene 27(41), 5443–5453 (2008)PubMedCrossRef

27.

A. Perren, P. Komminoth, P. Saremaslani, C. Matter, S. Feurer, J.A. Lees, P.U. Heitz, C. Eng, Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 157(4), 1097–1103 (2000)PubMedCrossRef

28.

M.L. Tena-Suck, A. Ortiz-Plata, H.A. de la Vega, Phosphatase and tensin homologue and pituitary tumor-transforming gene in pituitary adenomas. Clinical-pathologic and immunohistochemical analysis. Ann. Diagn. Pathol. 12(4), 275–282 (2008)PubMedCrossRef

29.

V. Vasko, M. Saji, E. Hardy, M. Kruhlak, A. Larin, V. Savchenko, M. Miyakawa, O. Isozaki, H. Murakami, T. Tsushima, K.D. Burman, C. De Micco, M.D. Ringel, Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet. 41(3), 161–170 (2004)PubMedCrossRef

30.

A.M. Martelli, I. Faenza, A.M. Billi, L. Manzoli, C. Evangelisti, F. Fala, L. Cocco, Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell. Signal. 18(8), 1101–1107 (2006)PubMedCrossRef

31.

L.C. Trotman, A. Alimonti, P.P. Scaglioni, J.A. Koutcher, C. Cordon-Cardo, P.P. Pandolfi, Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441(7092), 523–527 (2006)PubMedCrossRef

32.

S.S. Chaidarun, M.C. Eggo, M.C. Sheppard, P.M. Stewart, Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 135(5), 2012–2021 (1994)PubMedCrossRef

33.

V.K. LeRiche, S.L. Asa, S. Ezzat, Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J. Clin. Endocrinol. Metab. 81(2), 656–662 (1996)PubMedCrossRef

34.

M.L. Jaffrain-Rea, E. Petrangeli, C. Lubrano, G. Minniti, D. Di Stefano, F. Sciarra, L. Frati, G. Tamburrano, G. Cantore, A. Gulino, Epidermal growth factor binding sites in human pituitary macroadenomas. J. Endocrinol. 158(3), 425–433 (1998)PubMedCrossRef

35.

A. Rishi, M.C. Sharma, C. Sarkar, D. Jain, M. Singh, A.K. Mahapatra, V.S. Mehta, T.K. Das, A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol. India 58(3), 418–423 (2010)PubMedCrossRef

36.

M. Theodoropoulou, T. Arzberger, Y. Gruebler, M.L. Jaffrain-Rea, J. Schlegel, L. Schaaf, E. Petrangeli, M. Losa, G.K. Stalla, U. Pagotto, Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J. Endocrinol. 183(2), 385–394 (2004)PubMedCrossRef

37.

O. Cooper, G. Vlotides, H. Fukuoka, M.I. Greene, S. Melmed, Expression and function of ErbB receptors and ligands in the pituitary. Endocr. Relat. Cancer 18(6), R197–R211 (2011)PubMedCrossRef

38.

P.P. Di Fiore, G. Scita, Eps8 in the midst of GTPases. Int. J. Biochem. Cell Biol. 34(10), 1178–1183 (2002)PubMedCrossRef

39.

F. Fazioli, L. Minichiello, V. Matoska, P. Castagnino, T. Miki, W.T. Wong, P.P. Di Fiore, Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. EMBO J. 12(10), 3799–3808 (1993)PubMed

40.

M. Innocenti, E. Frittoli, I. Ponzanelli, J.R. Falck, S.M. Brachmann, P.P. Di Fiore, G. Scita, Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J. Cell Biol. 160(1), 17–23 (2003)PubMedCrossRef

41.

Y. Greenman, S. Melmed, Diagnosis and management of nonfunctioning pituitary tumors. Annu. Rev. Med. 47, 95–106 (1996)PubMedCrossRef

42.

I. Ewing, S. Pedder-Smith, G. Franchi, M. Ruscica, M. Emery, V. Vax, E. Garcia, S. Czirjak, Z. Hanzely, B. Kola, M. Korbonits, A.B. Grossman, A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin. Endocrinol (Oxf) 66(3), 348–352 (2007)CrossRef

43.

T.W. de Bruin, D.J. Kwekkeboom, J.W. Van’t Verlaat, J.C. Reubi, E.P. Krenning, S.W. Lamberts, R.J. Croughs, Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J. Clin. Endocrinol. Metab. 75(5), 1310–1317 (1992)PubMedCrossRef

44.

M. Gasperi, L. Petrini, R. Pilosu, M. Nardi, A. Marcello, F. Mastio, L. Bartalena, E. Martino, Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J. Endocrinol. Invest. 16(7), 541–543 (1993)PubMed

45.

T. Florio, S. Thellung, S. Arena, A. Corsaro, R. Spaziante, G. Gussoni, G. Acuto, M. Giusti, G. Giordano, G. Schettini, Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 141(4), 396–408 (1999)PubMedCrossRef

46.

H. Padova, H. Rubinfeld, M. Hadani, Z.R. Cohen, D. Nass, J.E. Taylor, M.D. Culler, I. Shimon, Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas. Mol. Cell. Endocrinol. 286(1–2), 214–218 (2008)PubMedCrossRef

47.

U. Renner, J. Mojto, M. Lange, O.A. Muller, K. von Werder, G.K. Stalla, Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 130(1), 80–91 (1994)PubMedCrossRef

48.

M.C. Zatelli, D. Piccin, C. Vignali, F. Tagliati, M.R. Ambrosio, M. Bondanelli, V. Cimino, A. Bianchi, H.A. Schmid, M. Scanarini, A. Pontecorvi, L. De Marinis, G. Maira, E.C. degli Uberti, Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr. Relat. Cancer 14(1), 91–102 (2007)PubMedCrossRef

49.

E. Hubina, A.M. Nanzer, M.R. Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M.R. Terreni, S. Khalaf, S. Jordan, S. Czirjak, Z. Hanzely, G.M. Nagy, M.I. Goth, A.B. Grossman, M. Korbonits, Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol. 155(2), 371–379 (2006)PubMedCrossRef

50.

M. Theodoropoulou, J. Zhang, S. Laupheimer, M. Paez-Pereda, C. Erneux, T. Florio, U. Pagotto, G.K. Stalla, Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 66(3), 1576–1582 (2006)PubMedCrossRef

51.

T. Florio, F. Barbieri, R. Spaziante, G. Zona, L.J. Hofland, P.M. van Koetsveld, R.A. Feelders, G.K. Stalla, M. Theodoropoulou, M.D. Culler, J. Dong, J.E. Taylor, J.P. Moreau, A. Saveanu, G. Gunz, H. Dufour, P. Jaquet, Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer 15(2), 583–596 (2008)PubMedCrossRef

52.

E. Peverelli, L. Olgiati, M. Locatelli, P. Magni, M.F. Fustini, G. Frank, G. Mantovani, P. Beck-Peccoz, A. Spada, A. Lania, The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett. 288(2), 170–176 (2010)PubMedCrossRef

53.

P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, M. Serio, A. Peri, Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 90(11), 6156–6161 (2005)PubMedCrossRef

54.

M. Korbonits, E. Carlsen, Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm. Res. 71(Suppl 2), 123–130 (2009)PubMedCrossRef

55.

V. Cerovac, J. Monteserin-Garcia, H. Rubinfeld, M. Buchfelder, M. Losa, T. Florio, M. Paez-Pereda, G.K. Stalla, M. Theodoropoulou, The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res. 70(2), 666–674 (2010)PubMedCrossRef

56.

M. Breuleux, M. Klopfenstein, C. Stephan, C.A. Doughty, L. Barys, S.M. Maira, D. Kwiatkowski, H.A. Lane, Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 8(4), 742–753 (2009)PubMedCrossRef

57.

A. Gorshtein, H. Rubinfeld, E. Kendler, M. Theodoropoulou, V. Cerovac, G.K. Stalla, Z.R. Cohen, M. Hadani, I. Shimon, Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr. Relat. Cancer 16(3), 1017–1027 (2009)PubMedCrossRef

58.

M.C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, M.R. Ambrosio, M. Lapparelli, M. Scanarini, E.C. Degli Uberti, Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 95(2), 968–976 (2010)PubMedCrossRef

59.

K.E. O’Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, J. Baselga, N. Rosen, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500–1508 (2006)PubMedCrossRef

60.

M. Lee, M. Theodoropoulou, J. Graw, F. Roncaroli, M.C. Zatelli, N.S. Pellegata, Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol. Cancer Ther. 10(8), 1450–1459 (2011)PubMedCrossRef

61.

B. Kola, M. Korbonits, S. Diaz-Cano, G. Kaltsas, D.G. Morris, S. Jordan, L. Metherell, M. Powell, S. Czirjak, G. Arnaldi, S. Bustin, M. Boscaro, F. Mantero, A.B. Grossman, Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin. Endocrinol (Oxf) 59(3), 328–338 (2003)CrossRef

62.

H. Rubinfeld, A. Gorshtein, E. Kendler, A. Kamar, O. Cohen, M. Hadani, I. Shimon IGF-1 induces tumorigenesis in human pituitary tumors—functional blockade of IGF-1 receptor as a novel therapeutic approach in non-functioning tumors, in 2nd ENEA Workshop, Aggressive Pituitary Tumors, Munich, 2011, p. 71

63.

F.M. Sirotnak, M.F. Zakowski, V.A. Miller, H.I. Scher, M.G. Kris, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6(12), 4885–4892 (2000)PubMed

64.

H. Fukuoka, O. Cooper, J. Mizutani, Y. Tong, S.G. Ren, S. Bannykh, S. Melmed, HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol. Endocrinol. 25(1), 92–103 (2011)PubMedCrossRef

65.

G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.G. Ren, S. Melmed, Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 68(15), 6377–6386 (2008)PubMedCrossRef

66.

U. Kumar, Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 40(2), 168–180 (2011)PubMedCrossRef

67.

X. Shi, B. Tao, H. He, Q. Sun, C. Fan, L. Bian, W. Zhao, Y.C. Lu, MicroRNAs-based network: a novel therapeutic agent in pituitary adenoma. Med. Hypotheses 78(3), 380–384 (2012)PubMedCrossRef

68.

X. Zhan, D.M. Desiderio, Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med. Genomics 3, 13 (2010)PubMedCrossRef

Title: PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas
Authors: Hadara Rubinfeld
Ilan Shimon
Publication date: 01-10-2012
Publisher: Springer US
Published in: Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9682-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Diagnosis and management of bilateral diaphyseal femoral fracture

Changing natural history of differentiated thyroid cancer

The use of a glucose spray device to control progression towards hypoglycaemia

Postprandial lipaemia suppresses endothelium-dependent arterial dilation in patients with hypothyroidism

Determining cut-off values for neck circumference as a measure of the metabolic syndrome amongst a South African cohort: the SABPA study

Andrological aspects of physical exercise and sport medicine

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page